中国组织工程研究

中国组织工程研究 ›› 2010, Vol. 14 ›› Issue (31): 5829-5832.doi: 10.3969/j.issn.1673-8225.2010.31.032

• 器官移植学术探讨 academic discussion of organ transplantation • 上一篇    下一篇

免疫抑制剂在肾移植中的应用

邹本警，王赞滔，张永利，杨  慧，王  峰，龙志新，李  莹   

  1. 辽河油田中心医院泌尿外科，辽宁省盘锦市  124010
  • 出版日期:2010-07-30 发布日期:2010-07-30
  • 作者简介:邹本警，男，1957年生，辽宁省岫岩县人，满族，1982年辽宁医学院毕业，主任医师，主要从事男性勃起功能障碍方面的研究。 Zoubenjing@medmail.com

Application of immunosuppressive agents to renal transplantation

Zou Ben-jing, Wang Zan-tao, Zhang Yong-li, Yang Hui, Wang Feng, Long Zhi-xin, Li Ying   

  1. Department of Urinary Surgery, Liaohe Oil Field Central Hospital, Panjin  124010, Liaoning Province, China
  • Online:2010-07-30 Published:2010-07-30
  • About author:Zou Ben-jing, Chief physician, Department of Urinary Surgery, Liaohe Oil Field Central Hospital, Panjin 124010, Liaoning Province, China Zoubenjing@medmail.com

PDF

534

被引次数

8

摘要：

目的：探讨免疫抑制剂在肾移植急性排斥反应中的作用和安全性。
方法：应用计算机检索2000-01/2009-10维普数据库和清华同方数据库。以“肾移植、免疫抑制剂、霉酚酸酯、他克莫司、环孢素、雷帕霉素、抗CD25单克隆抗体、抗CD3单克隆抗体”为检索词。文章所述内容应与免疫抑制剂预防、治疗肾移植术后急性排斥反应的研究相关。
结果：肾移植应用免疫抑制剂可以降低急性排斥发生率，使得移植肾短期存活明显改善，免疫抑制剂的肾毒性仍然是制约移植肾长期存活的重要因素。近年来出现新型免疫移植剂如雷帕霉素、FFY720等使得移植肾的长期存活成为可能。新型免疫抑制方案应着重减少毒副反应而不是单纯降低排斥反应发生率。
结论：随着近年来对移植免疫认识的深入，在免疫抑制剂上取得了很大的进步，给临床医生提供了越来越多的选择，但是令人满意的免疫抑制剂和免疫抑制方案还需不断探索。

关键词: 肾移植, 雷帕霉素, 环孢素A, 他克莫司, 免疫抑制剂

Abstract:

OBJECTIVE: To explore effects and safety of immunosuppressive agent on acute rejection following renal transplantation.
METHODS: We retrieved Vip and Tsinghua Tongfang Databases for relevant articles published from January 2000 to October 2009. The key words were “renal transplantation, immunosuppressive agent, mycophenolate, tacrolimus, cyclosporine, rapamycin, anti-CD25 monoclonal antibody, anti-CD3 monoclonal antibody”. The contents should be associated with the study concerning prevention and treatment of immunosuppressive agent on acute rejection following renal transplantation.
RESULTS: The use of immunosuppressive agent for renal transplantation can decrease the incidence rate of acute rejection, which can significantly improve the survival of transplanted kidney in a short period. However, the renal toxicity of immunosuppressive agent remains a key factor for restricting long-term survival of the transplanted kidney. Recently, novel immunosuppressive agents enable the long-term survival of transplanted kidney such as rapamycin and FFY720. Novel immunosuppressive agents should pay great attention on reducing adverse reactions, rather than the reduction in incidence rate of rejection alone.
CONCLUSION: With the deep understanding of transplantation immunity, we have made great progresses in immunosuppressive agents, which provide more and more choices for clinical physicians. However, satisfactory immunosuppressive agents and schemes deserve further investigations.

中图分类号: